Cancer pathogenesis and therapy最新文献

{"title":"Overview of skin cancer types and prevalence rates across continents","authors":"Amdad Hossain Roky ,&nbsp;Mohammed Murshedul Islam ,&nbsp;Abu Mohammed Fuad Ahasan ,&nbsp;Md Saqline Mostaq ,&nbsp;Md Zihad Mahmud ,&nbsp;Mohammad Nurul Amin ,&nbsp;Md Ashiq Mahmud","doi":"10.1016/j.cpt.2024.08.002","DOIUrl":"10.1016/j.cpt.2024.08.002","url":null,"abstract":"<div><div>Skin cancer is one of the most prevalent cancers in the world, and its incidence and mortality rates are increasing continuously, mostly in regions with white-skinned inhabitants. The types of skin cancer vary in their origin and clinical appearances and also differ in their extensiveness. The continents of the world have different scenarios of skin cancer prevalence. This review aims to explore the different types of skin cancer, their clinical features, and their worldwide prevalence based on the literature. Literature from different electronic databases, including Google Scholar, ResearchGate, PubMed, Scopus, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Elsevier, and Springer, were collected through a literature search using specific keywords such as “skin cancer”, “skin cancer types”, “melanoma”, “non-melanoma”, “skin cancer continental prevalence” or similar keywords. The search included English publications from 2000 to 2024. Melanoma skin cancer (MSC) ranks 17th in global prevalence, with the highest incidence and deaths occurring in Europe, However, Australia and New Zealand record the highest incidence and mortality rates. Asia has a lower incidence rate of melanoma, but a higher mortality rate. Superficial spreading melanoma (SSM) is the most common type of MSC. Non-melanoma skin cancers (NMSCs) have the highest incidence in North America, with the highest number of deaths occurring in Asia, Australia and New Zealand have the highest incidence rates for basal cell carcinoma (BCC). BCC is the most commonly diagnosed skin cancer worldwide and the most prevalent form of NMSCs; however, squamous cell carcinoma is the most aggressive form of NMSCs, causing more deaths. NMSCs are the most prevalent cancers worldwide, causing most skin cancer-related deaths. The prevalence of skin cancer rising globally, with several continents experiencing higher incidence and mortality rates. The types and subtypes of skin cancer are becoming more common among clinically diagnosed cancers. This review comprehensively describes skin cancer types and their prevalence worldwide. However, the actual prevalence of skin cancer in these countries should be investigated. Further research on the prevalence of skin cancer across different continents is required to develop more effective cancer management strategies and control the spread of the disease.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 2","pages":"Pages 89-100"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating multi-omics methods for personalized treatment of refractory chronic myelomonocytic leukemia with NRAS and TET2 mutations","authors":"Chuandong Hou ,&nbsp;Bo Yang ,&nbsp;Yue Wang ,&nbsp;Lili Cai ,&nbsp;Ran Qin ,&nbsp;Bo Guo ,&nbsp;Jie Geng ,&nbsp;XueChun Lu","doi":"10.1016/j.cpt.2024.12.001","DOIUrl":"10.1016/j.cpt.2024.12.001","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 2","pages":"Pages 173-175"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal stromal tumors with an uncommon primary mutation responded well to imatinib","authors":"Gilani Shahid,&nbsp;Mujeeb Qudsia,&nbsp;Ikram Naima,&nbsp;Khir Ibrahim","doi":"10.1016/j.cpt.2024.08.005","DOIUrl":"10.1016/j.cpt.2024.08.005","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 2","pages":"Pages 176-178"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover","authors":"","doi":"10.1016/S2949-7132(25)00018-7","DOIUrl":"10.1016/S2949-7132(25)00018-7","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 2","pages":"Page OFC"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications","authors":"Mahalakshmi Devaraji,&nbsp;Punniyakoti V. Thanikachalam","doi":"10.1016/j.cpt.2025.02.006","DOIUrl":"10.1016/j.cpt.2025.02.006","url":null,"abstract":"<div><div>Breast cancer remains one of the leading causes of cancer-related morbidity and mortality among women worldwide, necessitating the development of novel therapeutic strategies. Phytoconstituents, naturally plant-derived bioactive compounds, have emerged as promising agents for breast cancer therapy due to their multifaceted mechanisms of action. This review examines the role of phytoconstituents in inducing apoptosis, inhibiting breast cancer cell proliferation, and suppressing metastasis. Furthermore, the anti-angiogenic effects of these compounds are discussed, highlighting their potential to disrupt tumor vascularization. We also summarize the in vitro and in vivo study-derived preclinical evidence supporting the efficacy of phytoconstituents. The synergistic potential of phytoconstituents with conventional therapies is also explored, emphasizing their ability to enhance treatment efficacy while minimizing adverse effects. We also address the challenges and limitations in the clinical application of phytoconstituents, paving the way for future research. This review provides insights into the therapeutic potential of phytoconstituents in breast cancer and their underlying mechanisms, advocating for their integration into existing treatment regimens.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 5","pages":"Pages 364-382"},"PeriodicalIF":2.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing antibiotics: A dual-action approach against bacteria-induced cancer","authors":"Aditya Upadhyay ,&nbsp;Hem Chandra Jha ,&nbsp;Dharm Pal ,&nbsp;Awanish Kumar","doi":"10.1016/j.cpt.2025.02.005","DOIUrl":"10.1016/j.cpt.2025.02.005","url":null,"abstract":"<div><div>Antibiotic resistance and the growing burden of bacteria-induced cancers highlight the urgent need for innovative therapeutic approaches. Drug repurposing, leveraging pre-approved antibiotics for novel applications, is a promising strategy to address this challenge. Antibiotics designed to combat bacterial infections can inhibit microbial activity and target cellular mechanisms associated with oncogenesis. Chronic bacterial infections, such as those caused by <em>Salmonella typhi</em>, <em>Helicobacter pylori</em>, and <em>Escherichia coli</em>, contribute significantly to gallbladder, gastric, kidney, and bladder cancers. These infections induce inflammation, DNA damage, and the disruption of cellular pathways, promoting the development of cancer. Antibiotics such as doxycycline, rifampicin, and azithromycin demonstrate anticancer properties by inhibiting angiogenesis, inducing apoptosis, and regulating key pathways including the interleukin (IL)-6 signaling pathway and autophagy-related pathways. This dual action enhances chemotherapeutic efficacy and addresses bacteria-induced oncogenesis, offering a cost-effective and time-efficient alternative to traditional drug discovery. Herein, we review the intricate mechanisms by which bacteria-induced cancer arises and explore the groundbreaking potential of repurposing antibiotics as dual-action therapies in oncology. By elucidating the pivotal role of biofilms in persistent infections and highlighting untapped therapeutic opportunities in antibiotic repurposing, this review underscores a transformative approach to cancer treatment. This article explores the potential of repurposing antibiotic drugs for cancer treatment and highlights the prospects of drug repurposing strategies.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 6","pages":"Pages 473-483"},"PeriodicalIF":2.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting tumor-associated neutrophils: A promising strategy in lung cancer immunotherapy","authors":"Yongjun Wang ,&nbsp;Li Wang ,&nbsp;Zexu Wang,&nbsp;Yufang Guo,&nbsp;Xiuwei Zhang,&nbsp;Bing Wan","doi":"10.1016/j.cpt.2025.02.004","DOIUrl":"10.1016/j.cpt.2025.02.004","url":null,"abstract":"<div><div>Lung cancer is among the leading causes of cancer-related deaths worldwide, with treatment strategies primarily including surgery, chemotherapy, radiotherapy, and immunotherapy. Although immunotherapies targeting T cells and natural killer (NK) cells are widely used, therapies targeting neutrophils remain underdeveloped. Neutrophils are regarded as a specialized cell population that, once matured, lack the capacity for proliferation and are rapidly depleted in circulation, limiting their role to immune defense. However, recent discoveries have revealed that neutrophils represent a highly heterogeneous immune cell population, across diverse microenvironments. They are referred to as tumor-associated neutrophils when recruited to the tumor microenvironment. Initially, tumor-associated neutrophils were believed to primarily promote tumor growth and metastasis. Contrarily, emerging evidence indicates that tumor-associated neutrophils exhibit anti-tumor functions under specific conditions, acting as inhibitors during the initial growth or metastatic phases of lung cancer. This functional heterogeneity positions neutrophils as a promising focus for novel approaches to lung cancer immunotherapy. This review aims to explore the role of tumor-associated neutrophils in lung cancer progression and to investigate responses in the context of tumor control, thereby deepening the understanding of neutrophil function in lung cancer.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 6","pages":"Pages 466-472"},"PeriodicalIF":2.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of local consolidative radiotherapy with first-line chemoimmunotherapy in synchronous oligometastatic esophageal squamous cell carcinoma","authors":"Xinyi Wang ,&nbsp;Haixia Shen ,&nbsp;Miao Wang ,&nbsp;Baojia Qi ,&nbsp;Zhen Zhang ,&nbsp;Yang Yang ,&nbsp;Min Fang ,&nbsp;Jin Wang ,&nbsp;Yongling Ji","doi":"10.1016/j.cpt.2025.02.003","DOIUrl":"10.1016/j.cpt.2025.02.003","url":null,"abstract":"<div><h3>Background</h3><div>Synchronous oligometastatic esophageal squamous cell carcinoma (SOESCC), characterized by a limited number of metastases at diagnosis, represents a significant subset of esophageal squamous cell carcinoma. However, the optimal treatment modality for the condition has not been determined. Therefore, we aimed to evaluate the efficacy of local consolidative radiotherapy (cRT) for the primary tumor combined with first-line chemoimmunotherapy (CIT).</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 102 patients with SOESCC who underwent first-line CIT, either alone or in combination with cRT, between 2018 and 2022. We analyzed the progression-free survival (PFS) and overall survival (OS) in the two groups using propensity score matching (PSM). Univariate and multivariate Cox regression analyses were performed to identify prognostic factors associated with PFS and OS. Failure patterns were compared between groups.</div></div><div><h3>Results</h3><div>Patients who received the additional cRT had longer PFS (median PFS, 11.5 <em>vs.</em> 8.3 months, <em>P</em> = 0.009) than did those who received CIT only; however, no significant difference was noted in OS (median OS, 20.0 <em>vs.</em> 17.0 months, <em>P</em> = 0.410) between the two groups. These results remained consistent after PSM and multivariate Cox regression analyses (PFS: hazard ratio [HR] 0.539, 95% confidence interval [CI], 0.312–0.932, <em>P</em> = 0.027; OS: HR, 0.580, 95% CI, 0.307–1.095, <em>P</em> = 0.093). Notably, the pattern of failure in the CIT group was primarily characterized by locoregional failure, in contrast to the distant failure observed in the CIT + cRT group. Locoregional failure-free survival in the CIT + cRT group was significantly lower than that in the CIT group (<em>P</em> &lt; 0.001). Moreover, no statistically significant difference was observed in the incidence of treatment-related adverse events between the two groups.</div></div><div><h3>Conclusions</h3><div>In patients with SOESCC, the combination of local cRT and first-line CIT prolonged PFS without increasing treatment-related toxicity. In addition, cRT for primary tumor significantly reduced the incidence of locoregional failure. This synergistic approach appears to be a viable and potentially superior treatment strategy for the treatment of SOESCC.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 6","pages":"Pages 522-530"},"PeriodicalIF":2.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole transcriptome analysis identifies ALB-EEF1A1 fusion as a novel biomarker in metastatic colorectal cancer","authors":"Deeksha Rikhari ,&nbsp;Ankit Srivastava ,&nbsp;Sandhya Rai ,&nbsp;Mubashra ,&nbsp;Srinivas Patnaik ,&nbsp;Sameer Srivastava","doi":"10.1016/j.cpt.2025.02.002","DOIUrl":"10.1016/j.cpt.2025.02.002","url":null,"abstract":"<div><h3>Background</h3><div>Colorectal cancer (CRC) is a complex, heterogeneous disease characterized by frequent relapses and metastasis. Previous studies have reported that the invasion and progression of CRC in several cases can be controlled by targeting fusion genes. This study aimed to screen for potent fusion transcripts as potential molecular biomarkers and therapeutic targets for metastatic CRC (mCRC) using an <em>in silico</em> approach.</div></div><div><h3>Methods</h3><div>RNA sequencing (RNA-seq) data from 18 patients with primary CRC and matched normal and mCRC samples were derived from the same patient set. Novel fusion transcripts were screened using the Kallisto and Pizzly software, followed by Gene Ontology (GO), pathway analysis, transcription factor enrichment, and survival for functional enrichment analysis. Furthermore, the fusion transcripts’ utility as biomarkers was evaluated using a pan-cancer analysis.</div></div><div><h3>Results</h3><div>In total, 32 fusion genes unique to mCRC were identified. Hub gene analysis identified 17 novel fusion transcripts, and GO analysis revealed that these genes were enriched in different biological and molecular functions. Pathways significantly correlated with CRC included the complement and coagulation cascades, ferroptosis, interleukin-17 (<em>IL-17</em>) signaling pathway, and estrogen signaling pathway. We identified albumin-eukaryotic translation elongation factor 1 alpha 1 (<em>ALB-EEF1A1</em>) as unique to mCRC based on significant gene expression and survival outcomes. Moreover, its utility as a prognostic biomarker was confirmed using a pan-cancer analysis.</div></div><div><h3>Conclusions</h3><div><em>ALB-EEF1A1</em> may play a pivotal role in the metastatic transformation of primary CRC and significantly increase the risk of death. The identified <em>ALB-EEF1A1</em> fusion transcripts are promising novel molecular targets that may serve as prognostic and diagnostic biomarkers and treatment targets for mCRC in the future.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 5","pages":"Pages 420-433"},"PeriodicalIF":2.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers, isolation methods, and therapeutic implications of breast cancer stem cells","authors":"Peik Lin Teoh,&nbsp;Nurshafiqah Saini","doi":"10.1016/j.cpt.2025.01.006","DOIUrl":"10.1016/j.cpt.2025.01.006","url":null,"abstract":"<div><div>Breast cancer metastasis and relapse remain uncontrollable despite significant advancements in early diagnosis and treatment, resulting in increased mortality. Breast cancer is the most frequently diagnosed cancer in women worldwide and has become the leading cause of cancer-related deaths. Cancer stem cells (CSCs) may play significant roles in tumor initiation, maintenance, invasion, relapse, metastasis, and therapy resistance. Although this small, highly heterogeneous, and restricted population of CSCs has been extensively studied, their cellular and molecular physiology remains unclear. Nonetheless, CSCs have increasingly become an attractive therapeutic target for combating advanced, treatment-resistant cancers. This necessitates the development of effective and reliable methods for their isolation and enrichment. This review provides an overview of the key characteristics of breast cancer stem cells (BCSCs) and illustrates their role in therapeutic resistance. Furthermore, it highlights various mechanisms underlying cancer cell adaptability and therapy-induced resistance across different breast cancer subtypes. The commonly used methods for BCSC isolation and identification are also discussed, as they could facilitate a deeper understanding of tumorigenesis, metastasis, resistance, and relapse, consequently contributing to the development of more effective therapeutic strategies for breast cancer.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 5","pages":"Pages 392-401"},"PeriodicalIF":2.8,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}